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Making Ketamine Work in the Long Run
Terrence S. Early 1

Interventional Psychiatry Associates
Santa Barbara, CA, USA
Treatments such as ketamine psychotherapy face substantial financial and regulatory obstacles
to dissemination into widespread use. Newly patented medications are able to generate enough
capital to pay for studies required for FDA approval, personnel to apply for coverage on insurance
plans, and marketing to establish a successful launch. Ketamine is an older drug with considerable
evidence of efficacy for treatment resistant depression, and almost 50 years of data concerning
safety as an anesthetic agent. However, it can no longer be patented, so there is no incentive for
pharmaceutical companies to help get it into widespread use. In this paper we discuss some of
the complex issues surrounding use of ketamine in the outpatient setting and share information
and practice pearls that have been gathered through communication with other practitioners and
through direct experience with over 1000 treatments involving 120 patients in the last eight years.
The safety and appropriateness of intramuscular ketamine treatment in the outpatient psychiatric
office is discussed. We hope to help proponents of effective mental health interventions navigate
the actual and potential challenges involved in safe application of this treatment option outside of
hospital-based programs.
Keywords: Ketamine, psychotherapy, treatment-resistant depression,
post traumatic stress disorder, facilitated psychotherapy, dissemination
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etamine shows considerable efficacy for rapid
symptom relief in treatment resistant depression,
as well as an exceptional safety record as an
anesthetic agent with over nearly 50 years of clinical use.
Based on this evidence, ketamine appears to be a safe and
effective treatment for depression in outpatient settings.
At the same time, there are financial and regulatory
obstacles to dissemination of ketamine into widespread
use as a psychoactive medication. Newly patented
medications that show promise are typically able to
attract capital investment to pay for studies required by
the Food and Drug Administration (FDA) in order to
be approved for a specific use that will then be covered
by insurance plans. However, since ketamine can no
longer be patented, there is little financial incentive for
pharmaceutical for psychiatric applications. Given the
great need for effective new antidepressant strategies, and
the regulatory situation of ketamine treatment for mood
disorders, the dissemination of information regarding
its promising efficacy will necessarily proceed through
channels that are professional rather than commercial.
This report is based on the experience of the
author and a colleague (Jeffrey Becker) who have had
direct experience with over 1000 ketamine treatments

conducted with 120 patients over the past eight years;
in addition, the author is in communication with other
practitioners involved in ketamine treatment. Based
on this clinical experience, the current paper reports
on the actual and potential challenges involved in safe
application of intramuscular ketamine treatment for
psychological conditions such as depression in outpatient
settings.
Early’s interest in ketamine for depression began
after studying another anesthetic treatment approach
that never became mainstream—halothane isoelectric
therapy, using sevoflurane. Langer, Neumark, Koinig,
Graf, and Schoenbeck (1985) originally reported that
a related anesthetic agent, isoflurane, had a robust
antidepressant effect comparable to electroconvulsive
therapy (ECT) in an open-label trial. These results were
later replicated in a double-blinded trial (Langer et al.,
1995). Early found similar results with an open label
trial of sevoflurane therapy and a blinded comparison
to ECT (Early et al., unpublished results). Langer’s
isoflurane results were recently replicated by Weeks et
al. (2013). Halothane isoelectric therapy produces a
period of isoelectric electroencephalography (EEG)
similar to the state that follows an ECT-induced seizure,
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but without seizure-related cognitive side effects. Early
found it impossible to disseminate the technique, since
there was no mechanism to pay for anesthesiology and
hospital time to provide the treatment and no way to
obtain insurance coverage. Ketamine offered a less
expensive and less invasive alternative, and Early began
using it in 2007.
Becker examined the potential of ketamine on
depression in medical school and psychiatric residents at
UCLA. While looking at the NMDA receptor related
neurological substrates of transcendent experience it
became clear that ketamine might provide relief from
depression. Multiple clinical studies now confirm this
(Mathews & Zarate, 2013).
A Mandate for New Treatment Options
etamine represents the first new receptor-based
treatment for depression in decades and has the
potential to provide profound relief from great suffering.
In contrast with monoamine oxidase inhibitors and
tricyclic antidepressants that typically take weeks or
months to reach full effectiveness—and too often are
not effective at all—ketamine appears to provide rapid
relief from symptoms of depression, even in treatmentresistant cases (Zarate et al., 2006; Diazgranados et
al., 2010). Ketamine may represent a breakthrough
in the broader treatment of depression by offering
a novel pharmacological strategy focused on the
glutamatergic system, which may be more central to the
neurobiological mechanisms of mood disorders than the
serotonergic, noradrenergic, and dopaminergic systems
typically targeted in conventional pharmacological
treatments for mood disorder (Sanacora, Zarate, Krystal,
& Manji, 2008). There is evidence that ketamine
impacts the N-methyl-D-aspartate (NMDA) receptor
complex, which may itself mediate the delayed relief in
conventional treatment strategies; targeting this system
directly may represent a significantly more efficient
approach to the treatment of depression, and of mood
disorders more broadly, with a potentially large impact
on public health (Zarate et al., 2010).
The use of medications as psychotherapeutic
adjuncts has a long history in psychiatry (Kolb, 1985).
Barbiturate-facilitated psychotherapy, introduced by
Blackwenn (1930), was practiced for over 80 years to
treat conversion symptoms and traumatic war neurosis
or PTSD. The amytal and pentothal interviews were
developed later, along with other forms of drugfacilitated psychotherapy (Grinker & Speigel, 1945;
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Horsely, 1943; Lindemann, 1932). Sometimes called
abreactive psychotherapy, this approach was reported
to produce rapid relief of classic symptoms such as
flashbacks, nightmares, hypervigilence, and autonomic
hyper-reactivity (Hoch, 1946). Shovrin and Sargant
(1947) introduced an excitatory abreactive therapy using
ether and a variety of other agents, which later were used
to facilitate learning during psychotherapy (Sargant &
Slater, 1972).
Clearly the psychological effects that occur
with ketamine use as an antidepressant treatment touch
similar themes. While these older treatment techniques
were in danger of becoming a simple footnote in
psychiatric history, the improved safety and efficacy of
ketamine may eventually provide PTSD patients with
a viable treatment model in this mode. Indeed, Feder
et al. (2014) recently reported a robust effect on core
symptoms of PTSD with ketamine treatment.
However, perception of safety is likely to be
one of the largest challenges to broader acceptance of
ketamine’s role in psychiatry and the adoption of this
treatment within outpatient psychiatric offices. Despite
the fact that the outpatient psychiatric office is likely to
be the most efficient and effective in delivering treatment
to those in need, currently the majority of participating
practitioners are anesthesiologists or are at hospitalbased programs. The author hopes to clarify issues that
will allow broader adoption of this effective treatment
option in outpatient psychiatric clinics. Fear regarding
safety, both founded and often unfounded, should be
balanced by clinical evidence and an awareness of the
immense need for effective treatment delivery.
Safety of Low-Dose Ketamine Therapy
ntramuscular ketamine is generally considered safe
at subanesthetic doses, even in non-medical settings.
When used to induce general anesthesia, ketamine is
generally administered at a dose range of 3-8 mg/kg
IM or 1-4.5 mg/kg IV. The usual maintenance dose
for ketamine is an IV bolus of 0.1-0.5 mg/kg/minute.
Ketamine is often combined with other anesthetic
agents (such as propofol), and the dose is typically less in
this situation. Even at doses used for general anesthesia,
ketamine is associated with normal pharyngeal-laryngeal
reflexes, and usually cardiovascular and respiratory
stimulation, though there may occasionally be a transient
and minimal respiratory depression. In the low-dose
range 0.5-1 mg/kg, patients experience conscious sedation,
which means they remember the experience and respond
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to stimuli during the session. The physiologic effects of
subanesthetic ketamine provide a large margin of safety
in the treatment of depression through preservation of
responsivity to the practitioner, cardiac stimulation, and
maintanence of respiratory function and the gag reflex
(Hass & Harper, 1992).
Early and Becker have found use in the outpatient
setting to be remarkably free of adverse effects. Nausea
and occasional vomiting are the most common negative
effects, which are minimized by fasting 4-6 hours prior
to treatment or through the use of ondansetron. Anxiety
upon arrival at a session is common and is managed
through pretreatment discussion, clonidine and/or,
if needed, oral lorazepam. Blood pressure increases
of 5-10 mm/hg diastolic and 5-15 mm/hg systolic are
routine while heart rate increases of 10-20 bpm are seen
less commonly. We have not seen laryngospasm, severe
hypertension, respiratory distress, or severe agitation in
any of our cases. Our experience is consistent with the
experience of other clinicians with whom we consult and
with existing research.
Ketamine’s large safety margin provides
reassurance in settings where anesthesiologists and
monitoring are not available, such as the battlefield,
veterinary medicine, dentistry, and pediatric anesthesia.
O’Hara, Ganeshalingam, Gerrish, and Richardson
(2014) reported no adverse cardiac or respiratory events
after 131 sedation procedures by nursing with oral
ketamine, which is known to be more unpredictable
than IM or IV routes. In this study, an anesthesiology
consult was only required to further deepen sedation
or deal with excessive sedation. The National Clinical
Guideline Centre recommends that anesthesiology be
present only when ketamine is administered with opiates
(National Institute for Health and Care Excellence
[NICE], 2010). Even in full anesthesia, reflecting doses
up to 10 times those used for depression (e.g., 2 mg/kg IV
to 5 mg/kg IM), ketamine is remarkably safe. A review
of over 70,000 published anesthesia cases reported only
one ketamine-related fatality occurring in a seriously
medically compromised individual (Strayer & Nelson,
2008).
Given the confusion between full anesthesia
and conscious sedation a few issues do deserve further
clarification.
Respiratory Drive
Bourke, Malit, and Smith (1987) reported
minimal changes in respiratory drive with low-dose
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IV ketamine and a 5% drop in minute ventilation (l/
min) at 1.08 mg/kg. Mankikian, Cantineou, Sortene,
Clergue, and Viars (1986) reported no significant
change in respiratory functional residual capacity and
minute ventilation or tidal volume after full anesthetic
induction with 3 mg/kg. Morel, Forster, and Gemperle
(1986) reported increased respiratory drive, stable
arterial oxygen saturation, and end-tidal carbon dioxide
concentration with 1 mg/kg delivered IV. In addition,
bronchodilatory effects of ketamine, likely second to
circulating catecholamines, have been observed in canine
models. Ketamine has been used successfully in pediatric
status asthmaticus to facilitate intubation (Reich &
Silvay, 1989). While salivary secretions increase with
ketamine-induced full anesthesia this does not appear to
be a problem in conscious sedation due to intact swallow
reflexes and the vastly lower doses involved. In short,
respiratory drive remains intact with low dose (and even
high dose) ketamine (Hass & Harper, 1992).
Blood Pressure and Intercranial Pressure
It is understood that ketamine can increase
heart rate and arterial pressure (Hass & Harper, 1992) at
least partially through increases in free norepinephrine
(Zsigmond, Kelsch, & Kothary, 1973). Hypertension
should therefore be well controlled prior to treatment.
Mild increases in intracranial pressure have been noted
with ketamine, and Haas and Harper (1992) saw this as
a contraindication for use in vulnerable individuals.
Emergence Reaction
Ketamine’s psychological effects are often
reported in anesthesia and surgery research as an adverse
effect. While these effects may actually be inherent to
antidepressant effects, ketamine and other dissociative
drugs have been reported to exacerbate psychotic
symptoms in schizophrenia. While Carpenter (1999)
reported a lack of significant negative effects after
administration to 12 subjects with stable schizophrenia,
ketamine is not likely to be indicated for treatment in
cases involving primary psychosis.
Screening and Contraindications
iven physical safety considerations and the unique
psychological effects of ketamine, treatment with
minimal monitoring is relatively contraindicated in the
following physical and psychiatric conditions:

G

Uncontrolled Hypertension
Congestive Heart Failure
Other impaired cardiac status
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Severe Chronic Obstructive Pulmonary
Disease (COPD)
Severe Obesity
Increased intracranial or cerebrospinal (CSF)
pressure
Schizophrenia and Schizoaffective Disorder
Severe or Primitive Personality Disorders

ketamine’s tendency to increase arterial pressure. Our
list of medications that are held off from use for at least
24 hours prior to a ketamine session include:
Lamotrigine – due to its ability to block the
psychological effects of ketamine
Bupropion – due to observed anxiety and mild
agitation during treatment
Stimulants – for similar reasons as bupropion
and blood pressure elevation

Patient Selection and Evaluation
uring an initial evaluation, psychiatric and medical
history is reviewed along with lab work, past
treatment history, and history of substance abuse. Issues
relating to cardiac and pulmonary history, prior adverse
response to anesthesia, evidence of sleep apnea, and
history of primary psychosis are assessed. The patient is
considered a candidate for a ketamine session if they have
already failed multiple antidepressant trials and specific
contraindications do not exist. If the patient is severely
ill or suicidal, ketamine may be the treatment option
most likely to produce rapid, if temporary remission.
Consent for Treatment
A thorough informed consent process educates
patients to the psychological effects of treatment and
addresses the expectations and questions of the patient
and their family. Topics for discussion include acute and
residual side effects, potential risks and benefits, the offlabel nature of the treatment, and the research supporting
ketamine’s use in the treatment of depression. The scope
and duration of potential positive effects should be
discussed with every patient. Discussion regarding the
frequency and number of treatments required can be
informed by the naturalistic outcomes seen in ECT, in
that some patients respond after relatively few treatments
while others require a longer course of treatment.
The consent process helps to set realistic
but positive expectations, which may be an essential
element to success. With proper control of the physical
environment (e.g., dim light, music, reclining position)
the treatment experience is usually described by patients
as meaningful and positive. Psychotherapy is an essential
part of the process of recovery and is recommended
to every patient receiving ketamine treatment. Our
considerations regarding therapy are beyond the scope
of this paper, however, and will be provided in another
forum (see Becker, this issue, p. ___).
The Ketamine Treatment
atients are advised to take morning medications,
particularly antihypertensive medication given

These medications may be resumed later in the day after
the treatment session concludes.
When patients arrive there is discussion as to
their current psychiatric status and any appropriate
psychological assessments are completed (e.g., Beck
Depression Inventory), though particularly anxietyprovoking discussions are avoided. Patients are asked to
recline and spend time deep breathing as the treatment
is made ready and blood pressure is taken. Lights are
dimmed and soft music is provided if the patient has
not opted to bring their own. We remain with the
patient monitoring status, blood pressure and safety
considerations for 60-90 minutes during the active period
of the treatment, and patients will spend additional time
as needed to fully recover.
The setting is designed to facilitate a sense of
safety, comfort, and warmth. This is a lesson well learned
during early studies of psychedelic psychotherapy that
found the setting to contribute much to the effect of
treatment. There is stark contrast between ketamine
experienced in a florescent hospital setting surrounded
by detached strangers with a clinical stance versus a
warm and comfortable setting accompanied by loved
ones. This may be in part why we rarely see anxiety
or dysphoria to any significant degree. Patients usually
lie quietly during the session as we sit nearby to offer
assistance as needed.
Monitoring and Safety During Therapy
Ketamine produces conscious sedation within
3-5 minutes at 0.5 mg/kg IM, which means that
patients are responsive to verbal and physical prompts.
Intravenous infusions over 45 minutes are associated
with a more gradual alteration in consciousness, with
altered awareness usually reported within 10 minutes.
In every patient, vital signs and mental status should be
monitored before, at least once during the session, and
after the treatment concludes with an auto-inflatable
pressure cuff. To reduce the incidence of nausea
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and vomiting we recommend fasting for eight hours
before the initial treatment, reducing to four hours for
subsequent treatments in individuals without evidence of
delayed gastric emptying and who establish tolerance to
treatment side effects. Patients are advised to arrange for
other transportation home and agree not to drive after
treatment until they have slept a full night.
Some patients with controlled hypertension will
present with elevations due to anticipatory anxiety. In
these cases treatment is rescheduled and a prescription
for clonidine 0.1 or 0.2 mg PO 1-2 hours before arrival
is given. Clonidine is generally sufficient to reduce blood
pressure within protocol range, consistent with Tanaka
and Nishikawa (1994) who reported that administration
of clonidine 5 mcg/kg with ketamine in full anesthesia
abolished increases in arterial pressure seen in controls.
While it is also possible to use propranolol in these
situations, this may diminish the bronchodilatory effect
of ketamine (Reich & Silvay, 1989) and thus is an inferior
option and should not be used in patients with asthma.
While we have not witnessed severe anxiety or
agitation in our clinic lorazepam or alprazolam available
for oral or IM administration is always available.
Ondansetron 4-8 mg ODT or 2 mg liquid for IM
injection is also available for patients who experience
nausea despite fasting. Patients are advised to use
acetaminophen or ibuprofen for any headaches that may
occur after treatment. We also recommend that patients
take 500 mg of n-acetyl cysteine (NAC) prior to arrival
to support glutathione production.
Dosing and Duration of Effect
A target dose of 0.5 mg/kg IM may be initiated
in the first session at the clinician’s discretion or the
initial dose may be reduced by 25-50% in potentially
sensitive individuals. The total dose many also be divided
and separated by 10-15 minutes to reduce the speed of
onset and peak blood levels. Some patients have required
increased doses to improve efficacy.
Peak effects are felt within the first 10-20
minutes and patients are usually mostly recovered 90
minutes after injection. Some cognitive fog and fatigue
may linger for some hours, or until sleep resets brain
function.
Beneficial Effects
The medical literature now provides extensive
reports of clinical efficacy. The following are clinical
impressions based upon a broad range of patients and
treatment outcomes. Beneficial psychiatric effects on

depression, anxiety, and pain are usually seen during and
immediately following treatment, though some patients
begin to notice effects up to 48 hours later. Patients who
ultimately respond will almost always have a robust
antidepressant effect with the first treatment, though
this is not always the case.
In our experience, the duration of the effect
on depression is generally from one to four weeks. For
unclear reasons in some cases the effect fades after only a
few days while in others it may last for months. As such,
frequency of treatment must be adjusted to effect—
some patients only require a single session to resolve a
depressive episode while others may require a series of
treatments over a few weeks or months, similar to the
frequency of acute and maintenance ECT. We generally
treat patients once every 2-4 weeks to maintain remission
if depression recurs, concurrently adjusting medications
and psychotherapy to achieve a lasting remission.
Patients with both unipolar (typical and
atypical) and bipolar depression often respond to
ketamine offered in our clinic. We have seen patients
with psychotic depression improve with resolution of
psychosis. But, we have also observed a tendency for
mania to become more pronounced with ketamine.
On two occasions, we have had patients who failed to
respond to low dose treatment go on to respond to a
higher dose (3-8 mg/kg) received during an unrelated
surgical procedure. We have repeatedly seen rapid and
robust remission of severe suicidal ideation, consistent
with reports from preliminary research on ketamine
treatment (Price, Nock, Charney, & Mathew, 2009).
It is notable that even when the strong acute
effect on depression fades there tends to be residual
improvement in mood that persists. In addition, we
suspect that it is helpful for patients to experience an
interval of recovery, however brief, after prolonged
periods of depression. They are generally encouraged to
know that recovery is possible. Our patients routinely
report that ketamine provides them hope, reminding
them what it feels like to be free of depression.
Storage and Documention
Ketamine and syringes for IM delivery may be
ordered for office use through a pharmacy or a medical
supply company. Ketamine should be stored under double
lock-and-key as per Drug Enforcement Administration
(DEA) regulations for in-office storage of scheduled
medications. A log should be kept recording receipt and
use of medication including: date, amount received,
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amount used, amount wasted, expired medication that
is destroyed, vial number, patient name, indication, and
any other relevant comments.
Towards a Mechanism of
Action-Facilitated Emotional Learning
nduring psychological change often requires facing
emotionally painful topics, and exposure can be
a powerful treatment technique. We have found that
ketamine therapy facilitates this process in the days
following treatment, when patients encounter anxiety
cues during exposure therapy with reduced anxiety
and defensive responses. They discuss difficult areas
in psychotherapy with notably improved comfort and
insight.
It seems likely that ketamine may intervene
specifically at the crossroads of extinction and
reconsolidation, two processes capable of altering the
response to fearful memory (Centonze, Siracusano,
Calabresis, & Bernardi, 2005; Schiller, Raio, & Phelps,
2012; Soeter & Kindt, 2010).
Extinction of the response to fearful memory
can occur through prolonged exposure within a safe
environment. This allows a competing extinction
memory associated with safety rather than fear to
become associated with the trauma cues. However, short
exposure to fearful memory can instead initiate
reinforcement of a pathologic response through
reconsolidation (Schiller et al., 2012). With severe
PTSD, recall of the fearful memory during therapy often
produces freezing and dissociation, and the resulting
brief recall may reconsolidate and reinforce the memory,
rather than produce extinction (Centonze et al., 2005;
Myers, Carlezon, & Davis, 2011; Schiller et al., 2012).
In the days following ketamine therapy patients
typically find it easier to discuss and encounter reminders
of previous trauma. They do not generally experience
the extreme anxiety and freezing produced by previous
recall of the traumatic memory. Ketamine attenuates the
anxiety response produced by recalling the traumatic
memory, and thus patients engage in more extended
discussions of the traumatic memory, potentially
allowing for the development of extinction memory.
A Second Mechanism of
Action-Accelerated Self-Reliance
reatment-resistant patients often show complex
medical and psychiatric co-morbidity, social
isolation and avoidant behaviors that point toward
attachment difficulties. Attachment trauma, a common

feature of PTSD (Courtois, Ford, Herman, & Van der
Kolk, 2009), and perhaps of treatment resistant patients
in general, inhibits recovery through its detrimental
effects upon interpersonal intimacy and trust, selfconception, and life-perspective. It has become clear in
the last few decades that the neurobiological substrate of
change through psychotherapy includes improvements
in attachment patterns (Cozolino, 2010).
An important aspect of psychotherapy is
the provision of a mature psychological model as an
attachment structure that permits the development
of new and secure attachment patterns within and,
eventually, outside of the therapeutic relationship.
The therapeutic bond acts as proxy for the patient’s
relation to the Self (the personal and transpersonal
subconscious—capitalized here on in the tradition of
Jung to distinguish as the counter to ego) until authentic
restitution can develop, bringing this process inward
to allow a new orientation toward the outside world.
Unfortunately, this process often advances so slowly as
to be inconsistent with the resources of the patient. We
have come to see ketamine treatment as an accelerant
to this mysterious process. Perhaps through its capacity
to engender self-acceptance, intuition, and awareness,
patients more rapidly begin the process of relying upon
themselves, in a deep sense, rather than the therapeutic
bond.
Group Therapy
e provide a didactic component in a group
therapy setting, discussing topics such as
the neurobiology of depression, pain, and anxiety,
as well as an introduction to effective psychotherapy
and pharmacotherapy techniques for addressing
psychological symptoms. As an organizing principle,
ketamine patients participating in group therapy are
asked to focus their efforts in four areas.
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1. Automatic Scripts
The depth of each patient’s experience with
ketamine therapy usually exposes some of the
cognitive distortions they experience on a daily
level. Patients often have the nature of their limited
and disengaging programmatic scripts revealed to
them by the experience. They may appreciate a new
venue to consider and practice new scripts. Patients
complete a script/schema inventory and the group
may be educated about cognitive-behavioral links as
leverage points for growth.

2. Mindfulness
Mindfulness meditation has been shown to improve
attention and emotional self-regulation, as well
as enhancing white matter integrity around the
anterior cingulate gyrus, a cortical component of the
voluntary attention system (Tang, Lu, Fan, Yang, &
Posner, 2012; Tang & Posner, 2009). Mindfulness
skills are an important part of effective psychotherapy
for a broad variety of psychiatric conditions (Omidi,
Mohammadi, Zargar, & Akbari, 2013; Teasdale,
Segal, & Williams, 1995), and we find them helpful
in this setting as well. We commonly use the book,
Mindfulness: A Practical Guide to Finding Peace in
a Frantic World (Williams & Penman, 2011) to
educate about daily practice techniques. In addition,
we practice ten-minute mindfulness meditation
techniques during the group session.
3. Attachment / Compassion
We find that education regarding attachment theory
can help patients identify their specific attachment
patterns and facilitate insight-oriented change. After
years of observing treatments with ketamine therapy,
we believe that identifying the effect of attachment
issues on symptoms such as depression and social
detachment is particularly valuable. Here, we find
discussions on compassion and the use of lovingkindness or Metta Bhavana Meditation helpful
(Hofmann, Grossman, & Hinton, 2011). We also
discuss self-compassion, using exercises detailed by
Paul Gilbert (2009) in The Compassionate Mind: A
New Approach to Life’s Challenges.
4. Life Narrative / Mythic Reframing
Patients often experience substantial changes in
areas such as self-concept, life goals, and personal
understanding of life-meaning. We encourage
discussion of authentic truth and meaning and
support efforts to reframe major themes and
archetypal forces within their lives. Some patients
experience this process as occurring within a
particular religious tradition, but others do not.
We do not think it is the role of the therapist to
indoctrinate patients into any particular religious
tradition, but it is important to acknowledge the
spiritual nature of their efforts to gain a deeper
understanding of who they are. Ketamine permits a
“panoramic” view of life, not only one’s own life but
the life of others.
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Treatment Beyond Depression
ajor depression is a significantly heterogeneous
disorder that is often co-morbid with other
psychiatric conditions. As such we have been able to
observe the positive effect of ketamine upon a number
of other disorders.
Use in Pain
Chronic pain frequently becomes associated
with depression and anxiety. Fortunately, ketamine
has numerous beneficial effects on pain and many of
our patients report that ketamine is the most effective
treatment they have used for chronic pain. Complex
regional pain disorder (CRPS), also known as reflex
sympathetic dystrophy, is notoriously difficult to treat
but sometimes responds to high-dose ketamine protocols
offered in the United States and Germany (Schwartzmann
et al., 2009). In five CRPS patients we have also observed
low-dose ketamine providing noticeable acute pain
relief. Three of these patients gradually experienced a
permanent overall reduction in pain intensity over several
months. We have seen ketamine improve chronic daily
headaches, new daily persisting headache, neuropathic
pain, and chronic pelvic pain.
Use in PTSD and Anxiety Disorders
Following ketamine sessions, our patients with
PTSD often report reduced reaction to trauma cues, with
effects usually lasting from one to four weeks. During
this “grace period” patients seem to be more capable of
tolerating graded exposure. One patient, who was abused
and tormented with rodents as a child, could not be near
a rodent without experiencing dissociative anxiety and
flashbacks. Following ketamine, she was able to enter a
pet store and touch pet rats without severe anxiety. We
have seen patients tolerate discussion of emotionally
distressing events without feeling overwhelmed, and
therapists often report making considerable headway in
sessions scheduled a few days after ketamine treatment.
Patients with social phobia and generalized anxiety
disorder have generally reported benefits distinct from
the antidepressant effect as well. While we have not
treated enough patients with obsessive-compulsive
disorder (OCD) to have an opinion, two patients with
body dysmorphic disorders did not show any appreciable
effect with over six sessions.
Eating Disorders
We have observed one patient with severe mixed
anorexia and bulimia of 12 years duration recover over
the course of 12 months with treatments occurring
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once per week for a total of 48 treatments. Purging and
restriction patterns resolved completely. Psychological
growth was demonstrated through increasingly
meaningful and rewarding interpersonal relationships
and an ability to tolerate a healthy romantic dyad for the
first time. Mills, Park, Manara, and Merriman (1998)
reported a 70% response rate with multiple, 10 hour
extended infusions of a low dose of ketamine in a group
of patients hospitalized with anorexia and bulimia.
Conclusion
etamine treatment shows great potential as a new
pharmacological strategy in the treatment of
depression in that it produces relief of symptoms rapidly,
even in treatment resistant cases. Ketamine appears to
targets the glutamatergic system that may be central to
the neurobiology of mood disorders, and may represent
a more direct treatment strategy than that offered by
more conventional approaches. Its excellent safety record
has been demonstrated over decades. Despite potential
regulatory hurdles given that the drug cannot be patented,
and thus poses little opportunity for pharmacological
industry profit, the clinical observations presented here
are offered with the hope that ketamine treatment for
depression may find its way into more widespread use in
outpatient settings.
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